Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tessa Holyoake

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Nature|September 3, 2015
Cancer: Repositioned to kill stem cellsTessa Holyoake, David Vetrie
Clinical Lymphoma & Myeloma|December 17, 2009
The chronic myeloid leukemia stem cellEmma Nicholson, Tessa Holyoake
Leukemia & Lymphoma|June 30, 2004
Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemiaMark Drummond, Anne Lennard, Tim Brûmmendorf, et al.
Blood Cells, Molecules & Diseases|February 14, 2012
Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitroMohsin Shah, Paolo Gallipoli, John Lyons, et al.
British Journal of Haematology|April 27, 2011
Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population studyPaolo Gallipoli, Pat Shepherd, David Irvine, et al.
Pakistan Journal of Pharmaceutical Sciences|July 1, 2011
Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MSZafar Iqbal, Moira Elliott, David G Watson, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 16, 2010
Proceedings of the Third Global Workshop on Chronic Myeloid LeukemiaGiuseppe Saglio, Hagop Kantarjian, Tessa Holyoake, et al.
Plos Computational Biology|September 15, 2009
Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinibJasmine Foo, Mark W Drummond, Bayard Clarkson, et al.
British Journal of Haematology|April 6, 2007
GATA1 mutational analysis in chronic myeloid leukaemiaChristina Halsey, Chris Fisher, Gordon Strathdee, et al.
Lancet (London, England)|June 22, 2002
Not so NICE for CMLJohn Goldman, Jane Apperley, Richard Clark, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Nature|September 3, 2015
Cancer: Repositioned to kill stem cellsTessa Holyoake, David Vetrie
Clinical Lymphoma & Myeloma|December 17, 2009
The chronic myeloid leukemia stem cellEmma Nicholson, Tessa Holyoake
Leukemia & Lymphoma|June 30, 2004
Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemiaMark Drummond, Anne Lennard, Tim Brûmmendorf, et al.
Blood Cells, Molecules & Diseases|February 14, 2012
Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitroMohsin Shah, Paolo Gallipoli, John Lyons, et al.
British Journal of Haematology|April 27, 2011
Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population studyPaolo Gallipoli, Pat Shepherd, David Irvine, et al.
Pakistan Journal of Pharmaceutical Sciences|July 1, 2011
Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MSZafar Iqbal, Moira Elliott, David G Watson, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 16, 2010
Proceedings of the Third Global Workshop on Chronic Myeloid LeukemiaGiuseppe Saglio, Hagop Kantarjian, Tessa Holyoake, et al.
Plos Computational Biology|September 15, 2009
Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinibJasmine Foo, Mark W Drummond, Bayard Clarkson, et al.
British Journal of Haematology|April 6, 2007
GATA1 mutational analysis in chronic myeloid leukaemiaChristina Halsey, Chris Fisher, Gordon Strathdee, et al.
Lancet (London, England)|June 22, 2002
Not so NICE for CMLJohn Goldman, Jane Apperley, Richard Clark, et al.
Pageof 2